

**ALYSSA M. VANDERBEEK**  
530 W 157<sup>th</sup> St Apt 4A, New York, NY 10032  
(508) 505-8260 | [a.vanderbeek@columbia.edu](mailto:a.vanderbeek@columbia.edu)  
[Personal website](#) | [GitHub](#) | [LinkedIn](#)  
March 2019

## **EDUCATION**

---

**Columbia University**, New York, NY May 2020 (Expected)  
MS Biostatistics – GPA 3.75  
*Relevant Coursework: Data Science I, Biostatistical Methods I, Probability Theory*

**Wheaton College**, Norton, MA May 2016  
BA Mathematics, Minors Statistics & Economics – GPA 3.29  
*Relevant Coursework: Data Analysis, Introduction to Computer Science with Python, Econometrics, Linear Algebra*

## **AWARDS & HONORS**

---

Hispanic Scholarship Fund Scholar – Fall 2018

## **RESEARCH EXPERIENCE**

---

**Research Assistant**, Columbia University, New York, NY Sept 2018 – Present  
*Supervising Faculty: Codruta Chiuzan, PhD*

- Author R package based on [previous work](#) by Chiuzan
- Develop novel biostatistical methods based on previous work by Chiuzan

**Research Assistant**, [Dana-Farber Cancer Institute](#), Boston, MA Oct 2016 – July 2018  
*Principal Investigator: Brian M. Alexander, MD, MPH*

- Identify data sources; clean and maintain datasets; perform analysis and simulations in R
- Develop informatics tools to acquire and handle data from online sources
- Assist in development on biostatistical methods pertaining to clinical trial design/conduct
- Collaborate in manuscript writing (literature review, methods, and reporting results)

## **PUBLICATIONS**

---

\* Authors contributed equally

1. **Vanderbeek AM**, Rahman R, Fell G, Ventz S, Chen T, Redd R, Parmigiani G, Cloughesy T, Wen P, Trippa L, Alexander BM. The clinical trials landscape for glioblastoma: is it adequate to develop new treatments? *Neuro-Oncology*. 2018.
2. Rahman R, Ventz S, Fell G, **Vanderbeek AM**, Trippa L, Alexander BM. Divining Responder Populations from Survival Data. *Annals of Oncology: accepted manuscript*.

## MANUSCRIPTS

---

1. **Vanderbeek AM\***, Ventz S\*, Rahman R, Fell G, Trippa L, Alexander BM. To randomize, or not to randomize, that is the question: a meta-analytic methodology for determining the context-specific value of randomization. *Invited revision*.
2. Rahman R, Fell G, Ventz S, Arfe A, **Vanderbeek AM**, Trippa L, Alexander BM. Deviation from the proportional hazards assumption in randomized phase 3 oncology clinical trials: prevalence, associations, and implications. *Invited revision*.

## OTHER RELEVANT EXPERIENCE

---

**Information Analyst**, Definitive Healthcare, Natick, MA Aug 2016 – Oct 2016

- Web application development and maintenance (use of SQL Server, HTML)
- Relational database management using SQL Server (5 databases)
- Create custom data reports for clients

**Student**, [Summer Institute for Training in Biostatistics](#), Boston University, Boston, MA Summer 2015

- Competitive six-week full-time intensive introduction to biostatistics
- Training in SAS and using data from the Framingham Heart Study

## RELEVANT PROJECTS

---

1. *The clinical trials landscape for glioblastoma: is it adequate to develop new treatments?*  
This project was a meta-analysis of clinical trials conducted for glioblastoma between 2005 and 2016. We wrote software to leverage *ClinicalTrials.gov* and *PubMed*, cross-referencing registered trials and their publications with the goal of identifying potential areas of inefficiencies. The publication of results can be found [here](#).
2. *Visualizing wearable technology activity – Data Science I midterm project*  
Using data from one individual over a span of several months, I examined trends in activity and visualized these findings. The GitHub repository for this project can be found [here](#).

## SKILLS

---

**Computer:** R, SQL, LaTeX, SAS, HTML5, Stata, Python

**Language:** English (native), French (intermediate)